Coccidioidomycosis in rheumatology patients

Incidence and potential risk factors

Lester E. Mertz, Janis E. Blair

Research output: Chapter in Book/Report/Conference proceedingConference contribution

35 Citations (Scopus)

Abstract

Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9% of the overall practice and in 3.1-3.6% of patients with rheumatoid arthritis (RA). The annual incidence was 1%in patients recently diagnosed with RA and 2% among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.

Original languageEnglish (US)
Title of host publicationAnnals of the New York Academy of Sciences
Pages343-357
Number of pages15
Volume1111
DOIs
StatePublished - Sep 2007

Publication series

NameAnnals of the New York Academy of Sciences
Volume1111
ISSN (Print)00778923
ISSN (Electronic)17496632

Fingerprint

Coccidioidomycosis
Rheumatology
Incidence
Rheumatic Diseases
Immunosuppressive Agents
Rheumatoid Arthritis
Adrenal Cortex Hormones
Tumor Necrosis Factor-alpha
Southwestern United States
Mycoses
Joints
Therapeutics

Keywords

  • Coccidioidomycosis
  • Corticosteroids
  • Disease-modifying antirheumatic drug
  • Immunosuppression
  • Incidence
  • Rheumatoid arthritis
  • Tumor necrosis factor inhibitors

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Mertz, L. E., & Blair, J. E. (2007). Coccidioidomycosis in rheumatology patients: Incidence and potential risk factors. In Annals of the New York Academy of Sciences (Vol. 1111, pp. 343-357). (Annals of the New York Academy of Sciences; Vol. 1111). https://doi.org/10.1196/annals.1406.027

Coccidioidomycosis in rheumatology patients : Incidence and potential risk factors. / Mertz, Lester E.; Blair, Janis E.

Annals of the New York Academy of Sciences. Vol. 1111 2007. p. 343-357 (Annals of the New York Academy of Sciences; Vol. 1111).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Mertz, LE & Blair, JE 2007, Coccidioidomycosis in rheumatology patients: Incidence and potential risk factors. in Annals of the New York Academy of Sciences. vol. 1111, Annals of the New York Academy of Sciences, vol. 1111, pp. 343-357. https://doi.org/10.1196/annals.1406.027
Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: Incidence and potential risk factors. In Annals of the New York Academy of Sciences. Vol. 1111. 2007. p. 343-357. (Annals of the New York Academy of Sciences). https://doi.org/10.1196/annals.1406.027
Mertz, Lester E. ; Blair, Janis E. / Coccidioidomycosis in rheumatology patients : Incidence and potential risk factors. Annals of the New York Academy of Sciences. Vol. 1111 2007. pp. 343-357 (Annals of the New York Academy of Sciences).
@inproceedings{e315fcd64f5344a9a47d89fc89049158,
title = "Coccidioidomycosis in rheumatology patients: Incidence and potential risk factors",
abstract = "Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9{\%} of the overall practice and in 3.1-3.6{\%} of patients with rheumatoid arthritis (RA). The annual incidence was 1{\%}in patients recently diagnosed with RA and 2{\%} among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.",
keywords = "Coccidioidomycosis, Corticosteroids, Disease-modifying antirheumatic drug, Immunosuppression, Incidence, Rheumatoid arthritis, Tumor necrosis factor inhibitors",
author = "Mertz, {Lester E.} and Blair, {Janis E.}",
year = "2007",
month = "9",
doi = "10.1196/annals.1406.027",
language = "English (US)",
isbn = "1573316881",
volume = "1111",
series = "Annals of the New York Academy of Sciences",
pages = "343--357",
booktitle = "Annals of the New York Academy of Sciences",

}

TY - GEN

T1 - Coccidioidomycosis in rheumatology patients

T2 - Incidence and potential risk factors

AU - Mertz, Lester E.

AU - Blair, Janis E.

PY - 2007/9

Y1 - 2007/9

N2 - Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9% of the overall practice and in 3.1-3.6% of patients with rheumatoid arthritis (RA). The annual incidence was 1%in patients recently diagnosed with RA and 2% among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.

AB - Coccidioidomycosis is a potentially serious fungal infection contracted in endemic areas of the desert southwestern United States. Limited information exists about its incidence and clinical course in patients with rheumatic diseases, who may be at higher risk of symptomatic or disseminated coccidioidomycosis because of either the rheumatic disease itself or its treatment. We analyzed the incidence and risk factors for symptomatic and complicated coccidioidomycosis in our academic rheumatology practice in central Arizona. Between January 1, 2000, and June 30, 2006, coccidioidomycosis was diagnosed in 1.9% of the overall practice and in 3.1-3.6% of patients with rheumatoid arthritis (RA). The annual incidence was 1%in patients recently diagnosed with RA and 2% among patients with recently initiated infliximab treatment. Coccidioidomycosis was identified only in patients with inflammatory rheumatic diseases and extrathoracic dissemination occurred only to joints in two patients. Corticosteroids, immunosuppressive medications, and tumor necrosis factor inhibitors (TNFIs) appeared to be risk factors for symptomatic, but not disseminated coccidioidomycosis.

KW - Coccidioidomycosis

KW - Corticosteroids

KW - Disease-modifying antirheumatic drug

KW - Immunosuppression

KW - Incidence

KW - Rheumatoid arthritis

KW - Tumor necrosis factor inhibitors

UR - http://www.scopus.com/inward/record.url?scp=35348900733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=35348900733&partnerID=8YFLogxK

U2 - 10.1196/annals.1406.027

DO - 10.1196/annals.1406.027

M3 - Conference contribution

SN - 1573316881

SN - 9781573316880

VL - 1111

T3 - Annals of the New York Academy of Sciences

SP - 343

EP - 357

BT - Annals of the New York Academy of Sciences

ER -